Clinical Trial Update: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing weekly basal insulin Insulin Efsitora Alfa (LY3209590) to insulin glargine in adults with type 2 diabetes on multiple daily injections. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Efsitora Alfa (LY3209590)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | Phase 3 | Status: COMPLETED | Results posted: 2025-04-27